Haploidentical transplantation in patients with acquired aplastic anemia | Aplastic Anemia and MDS International Foundation

Haploidentical transplantation in patients with acquired aplastic anemia

Journal Title: 
Bone Marrow Transplant
Author(s): 
Ciceri F, Lupo-Stanghellini MT, Korthof ET
Primary Author: 
Ciceri F
Original Publication Date: 
Monday, January 7, 2013

Haploidentical SCT (haplo-SCT) has been considered a therapeutic option in patients with acquired severe aplastic anemia (SAA) failing at least one course of immune suppressive therapy with antithymocyte globulin and lacking an HLA-matched related or unrelated donor. The platforms of both ex vivo T-cell-depleted and unmanipulated grafts have been explored in children and adults. Overall, the primary objective of a stable haploidentical hematopoietic engraftment with a low rate of GVHD is unmet in a significant proportion of patients undergoing haplo-SCT for SAA. Haploidentical transplants for refractory SAA should be performed in a specialist center with major experience in hematopoietic SCT procedures and preferably performed within the framework of a local clinical protocol designed specifically to address the prevention of graft rejection and GVHD

Bone Marrow Diseases: